Supporting Information

Mannopyranoside Glycolipids Inhibit Mycobacterial and Biofilm Growth and Potentiate Isoniazid Inhibition Activities in *M. smegmatis*

Avishek Mahapa^{+, [a]} Gopal Ch Samanta^{+, [b]} Krishnagopal Maiti^{+, [b]} Dipankar Chatterji,^{*, [a]} and Narayanaswamy Jayaraman^{*, [b]}

cbic_201900040_sm_miscellaneous_information.pdf

Supporting Information

Contents

	Page
Figure S1. ^1H NMR spectrum of 6	3
Figure S2. ^{13}C NMR spectrum of 6	3
Figure S3. ^1H NMR spectrum of 7	4
Figure S4. ^{13}C NMR spectrum of 7	4
Figure S5. COSY NMR spectrum of 7	5
Figure S6. HMQC NMR spectrum of 7	5
Figure S7. ^1H NMR spectrum of 8	6
Figure S8. ^{13}C NMR spectrum of 8	6
Figure S9. COSY NMR spectrum of 8	7
Figure S10. HMQC NMR spectrum of 8	7
Figure S11. ^1H NMR spectrum of 1	8
Figure S12. ^{13}C NMR spectrum of 1	8
Figure S13. ^1H NMR spectrum of protected derivative of 2	9
Figure S14. ^{13}C NMR spectrum of protected derivative of 2 .	9
Figure S15. ^1H NMR spectrum of 2	10
Figure S16. ^{13}C NMR spectrum of 2	10
Figure S17. ^1H NMR spectrum of 13	11
Figure S18. ^{13}C NMR spectrum of 13	11
Figure S19. ^1H NMR spectrum of protected derivative of 3	12
Figure S20. ^{13}C NMR spectrum of protected derivative of 3	12

Figure S21. ^1H NMR spectrum of 3	13
Figure S22. ^{13}C NMR spectrum of 3	13
Figure S23. ^1H NMR spectrum of protected derivative of 4	14
Figure S24. ^{13}C NMR spectrum of protected derivative of 4	14
Figure S25. ^1H NMR spectrum of 4	15
Figure S26. ^{13}C NMR spectrum of 4	15
Figure S27. Bacterial growth inhibition in the presence of synthetic glycolipids at a concentration of $50\text{ }\mu\text{g mL}^{-1}$	16
Figure S28. Bacterial biofilm inhibition assay in the presence of synthetic glycolipids at a concentration of $50\text{ }\mu\text{g mL}^{-1}$.	17
Figure S29. Bacterial growth in the presence of synthetic glycolipids at a concentration of $50\text{ }\mu\text{g mL}^{-1}$ and isoniazid $2\text{ }\mu\text{g mL}^{-1}$.	18
Figure S30. Bacterial growth in the presence of synthetic glycolipids at concentration of $50\text{ }\mu\text{g mL}^{-1}$ and isoniazid $7\text{ }\mu\text{g mL}^{-1}$.	19
Figure S31. Biofilm inhibition assay in the presence of isoniazid $20\text{ }\mu\text{g mL}^{-1}$ and synthetic glycolipids $50\text{ }\mu\text{g mL}^{-1}$.	20
Figure S32. Biofilm inhibition assay in the presence of isoniazid $40\text{ }\mu\text{g mL}^{-1}$ and synthetic glycolipids $50\text{ }\mu\text{g mL}^{-1}$.	21

Figure S1. ¹H NMR spectrum of **6** (CDCl₃, 400 MHz).

Figure S2. ¹³C NMR spectrum of **6** (CDCl₃, 100 MHz).

Figure S3. ^1H NMR spectrum of **7** (CDCl₃, 400 MHz).

Figure S4. ^{13}C NMR spectrum of **7** (CDCl₃, 100 MHz).

Figure S5. COSY NMR spectrum of **7** (CDCl₃, 400 MHz).

Figure S6. HMBC NMR spectrum of **7** (CDCl₃, 100 MHz).

Figure S7. ¹H NMR spectrum of **8** (CDCl₃, 400 MHz).

Figure S8. ¹³C NMR spectrum of **8** (CDCl₃, 100 MHz).

Figure S9. COSY NMR spectrum of **8** (CDCl₃, 400 MHz).

Figure S10. HMQC NMR spectrum of **8** (CDCl₃, 100 MHz).

Figure S11. ¹H NMR spectrum of **1** (CDCl₃, 400 MHz).

Figure S12. ¹³C NMR spectrum of **1** (CDCl₃, 100 MHz).

Figure S13. ^1H NMR spectrum of protected derivative of **2** (CDCl₃, 400 MHz).

Figure S14. ^{13}C NMR spectrum of protected derivative of **2** (CDCl₃, 100 MHz).

Figure S15. ^1H NMR spectrum of **2** (CDCl₃, 400 MHz).

Figure S16. ^{13}C NMR spectrum of **2** (CDCl₃, 100 MHz).

Figure S17. ^1H NMR spectrum of **13** (CDCl_3 , 400 MHz).

Figure S18. ^{13}C NMR spectrum of **13** (CDCl_3 , 100 MHz).

Figure S19. ¹H NMR spectrum of protected derivative of **3** (CDCl₃, 400 MHz).

Figure S20. ¹³C NMR spectrum of protected derivative of **3** (CDCl₃, 100 MHz).

Figure S21. ¹H NMR spectrum of **3** (DMSO-d₆, 400 MHz).

Figure S22. ¹³C NMR spectrum of **3** (DMSO-d₆, 100 MHz).

Figure S23. ^1H NMR spectrum of protected derivative of **4** (CDCl_3 , 400 MHz).

Figure S24. ^{13}C NMR spectrum of protected derivative of **4** (CDCl_3 , 100 MHz).

Figure S25. ¹H NMR spectrum of **4** (CDCl₃, 400 MHz).

Figure S26. ¹³C NMR spectrum of **4** (CDCl₃, 100 MHz).

Figure S27. Bacterial growth inhibition in the presence of synthetic glycolipids at a concentration of 50 $\mu\text{g mL}^{-1}$, relative to the NC (Negative control).

Figure S28. Bacterial biofilm inhibition assay in the presence of synthetic glycolipids at a concentration of $50 \mu\text{g mL}^{-1}$, relative to the NC (Negative control).

Figure S29. Bacterial growth in the presence of synthetic glycolipids at a concentration of 50 µg mL⁻¹ and isoniazid 2 µg mL⁻¹.

Figure S30. Bacterial growth in the presence of synthetic glycolipids at a concentration of 50 µg mL⁻¹ and isoniazid 7 µg mL⁻¹.

Figure S31. Biofilm inhibition assay in the presence of isoniazid 20 µg mL⁻¹ and synthetic glycolipids 50 µg mL⁻¹.

Figure S32. Biofilm inhibition assay in the presence of Isoniazid (40 $\mu\text{g mL}^{-1}$) and synthetic glycolipids (50 $\mu\text{g mL}^{-1}$).